· Malignant neoplasm of endocervix. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code. C53.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C53.0 became effective on October 1, 2021.
C53.0 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of endocervix. The code C53.0 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions. The ICD-10-CM code C53.0 might also be used to specify conditions or terms like adenocarcinoma of cervix, …
· C53.0 is a valid billable ICD-10 diagnosis code for Malignant neoplasm of endocervix. It is found in the 2022 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 .
This page provides the full title for the ICD diagnosis code “C53.0 Malignant neoplasm: Endocervix” and its subcategories.
Endocervical adenocarcinoma is a type of cervical cancer. It develops in the cervix from the glandular cells normally found in the endocervical canal. Most tumours develop from a non-invasive type of cancer called endocervical adenocarcinoma in situ (AIS).
2022 ICD-10-CM Diagnosis Code Z51. 11: Encounter for antineoplastic chemotherapy.
Myometrial cancer (C54. 2) Cervical cancer, unspecified (C53. 9)
ICD-10 code Z12 for Encounter for screening for malignant neoplasms is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Encounter for antineoplastic immunotherapyICD-10 code Z51. 12 for Encounter for antineoplastic immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
A malignant neoplasm (NEE-oh-plaz-um) is another term for a cancerous tumor. The term “neoplasm” refers to an abnormal growth of tissue. The term “malignant” means the tumor is cancerous and is likely to spread (metastasize) beyond its point of origin.
A screening Pap test (also called a Pap smear) is a laboratory test used to detect early cervical cancer. A health care provider takes a sample of cervical cells and interprets the test results.
Z12.4 Encounter for screening for malignant neoplasm of cervix.
ICD-10-CM Code for Personal history of malignant neoplasm of breast Z85. 3.
A screening colonoscopy should be reported with the following International Classification of Diseases, 10th edition (ICD-10) codes: Z12. 11: Encounter for screening for malignant neoplasm of the colon.
The term "malignant neoplasm" means that a tumor is cancerous. A doctor may suspect this diagnosis based on observation — such as during a colonoscopy — but usually a biopsy of the lesion or mass is needed to tell for sure whether it is malignant or benign (not cancerous).
For example, Z12. 31 (Encounter for screening mammogram for malignant neoplasm of breast) is the correct code to use when you are ordering a routine mammogram for a patient.
The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection.
It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests.
Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix.
C53.0 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of endocervix. The code C53.0 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions. The code C53.0 is applicable to female patients only.
Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer.
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code: 1 Adenocarcinoma of cervix 2 Carcinoma of cervix 3 Carcinoma of endocervix 4 Endocervical adenocarcinoma 5 Malignant neoplasm of endocervical canal 6 Malignant neoplasm of endocervical gland 7 Malignant neoplasm of endocervix 8 Primary adenocarcinoma of cervix uteri 9 Primary adenocarcinoma of endocervix 10 Primary malignant neoplasm of endocervix
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...